(Q35826686)

English

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

scientific article published in February 2005

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

8

object named as

Jos H Beijnen

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Eric C. M. van Gorp

6

object named as

Eric C M van Gorp

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Alwin D R Huitema

2

object named as

Alwin D R Huitema

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

author name string

Bregt S Kappelhoff

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Kristel M L Crommentuyn

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jan W Mulder

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Pieter L Meenhorst

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Albert T A Mairuhu

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

59

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

174-182

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

High variability of plasma drug concentrations in dual protease inhibitor regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

27 July 2018

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Low-dose ritonavir moderately enhances nelfinavir exposure

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02241.X

21 January 2018

The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

24 September 2018

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884743

24 September 2018

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

https://pubmed.ncbi.nlm.nih.gov/15676039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/15676039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/15676039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/15676039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/15676039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2004.02241.X

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35826686&oldid=2143464786"